恩替卡韦联合水飞蓟宾药物治疗乙型病毒性肝炎肝硬化的临床效果观察

Observation on the clinical effect of entecavir combined with silybin in the treatment of hepatitis B cirrhosis

目的分析乙型病毒性肝炎肝硬化行恩替卡韦联合水飞蓟宾药物治疗的临床效果。方法64例乙型病毒性肝炎肝硬化患者,经随机抽签法分为对照组和观察组,每组32例。两组患者均行抗病毒治疗,对照组给予恩替卡韦治疗,观察组患者在对照组基础上联合水飞蓟宾药物治疗。比较两组患者肝功能指标及不良反应发生情况。结果治疗后,观察组患者血清总胆红素(26.34±3.55)μmol/L、丙氨酸氨基转移酶(45.55±20.09)U/L低于对照组的(28.63±3.61)μmol/L、(62.65±20.75)U/L,白蛋白(37.89±4.77)g/L高于对照组的(33.79±5.34)g/L,凝血酶原时间(11.85±2.31)s短于对照组的(13.72±3.36)s,差异具有统计学意义(P<0.05)。观察组患者不良反应发生率为6.25%,低于对照组的25.00%,差异具有统计学意义(P<0.05)。结论对乙型病毒性肝炎肝硬化患者给予恩替卡韦联合水飞蓟宾药物治疗的临床价值显著,能够有效改善肝功能,控制不良反应发生风险,值得临床推广应用。

Objective To analyze the clinical effect of entecavir combined with silybin in the treatment of hepatitis B cirrhosis.Methods A total of 64 patients with hepatitis B cirrhosis were randomly divided into control group and observation group with 32 cases in each group.Both groups received antiviral treatment,the control group was treated with entecavir,and the observation group was treated with silybin on the basis of the control group.The liver function indexes and occurrence of adverse reactions were compared between the two groups.Results After treatment,the serum total bilirubin(26.34±3.55)μmol/L and alanine aminotransferase(45.55±20.09)U/L of the observation group were lower than(28.63±3.61)μmol/L and(62.65±20.75)U/L of the control group,and the albumin(37.89±4.77)g/L was higher than(33.79±5.34)g/L of the control group,and prothrombin time(11.85±2.31)s was shorter than(13.72±3.36)s of the control group.All differences were statistically significant(P<0.05).The incidence of adverse reactions in the observation group was 6.25%,which was lower than 25.00% in the control group,and the difference was statistically significant(P<0.05).Conclusion Entecavir combined with silybin has ideal value in the treatment of hepatitis B cirrhosis,which is beneficial to improve liver function and control the risk of adverse reactions.It is worthy of clinical promotion and application.